Siderowf A - Search Results

1

Cognitive performance and neuropsychiatric symptoms in early, untreated Parkinson's disease.

Weintraub D, Simuni T, Caspell-Garcia C, Coffey C, Lasch S, Siderowf A, Aarsland D, Barone P, Burn D, Chahine LM, Eberling J, Espay AJ, Foster ED, Leverenz JB, Litvan I, Richard I, Troyer MD, Hawkins KA; Parkinson's Progression Markers Initiative. Weintraub D, et al. Among authors: siderowf a. Mov Disord. 2015 Jun;30(7):919-27. doi: 10.1002/mds.26170. Epub 2015 Mar 4. Mov Disord. 2015. PMID: 25737166 Free PMC article.

2

Cost-effectiveness analysis in Parkinson's disease: determining the value of interventions.

Siderowf AD, Holloway RG, Stern MB. Siderowf AD, et al. Mov Disord. 2000 May;15(3):439-45. doi: 10.1002/1531-8257(200005)15:3<439::AID-MDS1004>3.0.CO;2-F. Mov Disord. 2000. PMID: 10830407 Review. No abstract available.

3

Bilateral stimulation of the subthalamic nucleus in patients with Parkinson disease: a study of efficacy and safety.

Simuni T, Jaggi JL, Mulholland H, Hurtig HI, Colcher A, Siderowf AD, Ravina B, Skolnick BE, Goldstein R, Stern MB, Baltuch GH. Simuni T, et al. Among authors: siderowf ad. J Neurosurg. 2002 Apr;96(4):666-72. doi: 10.3171/jns.2002.96.4.0666. J Neurosurg. 2002. PMID: 11990805 Clinical Trial.

4

Test-retest reliability of the unified Parkinson's disease rating scale in patients with early Parkinson's disease: results from a multicenter clinical trial.

Siderowf A, McDermott M, Kieburtz K, Blindauer K, Plumb S, Shoulson I; Parkinson Study Group. Siderowf A, et al. Mov Disord. 2002 Jul;17(4):758-63. doi: 10.1002/mds.10011. Mov Disord. 2002. PMID: 12210871 Clinical Trial.

5

Development of quality of care indicators for Parkinson's disease.

Cheng EM, Siderowf A, Swarztrauber K, Eisa M, Lee M, Vickrey BG. Cheng EM, et al. Among authors: siderowf a. Mov Disord. 2004 Feb;19(2):136-50. doi: 10.1002/mds.10664. Mov Disord. 2004. PMID: 14978668 Review.

6

Striatal dopamine transporter imaging correlates with anxiety and depression symptoms in Parkinson's disease.

Weintraub D, Newberg AB, Cary MS, Siderowf AD, Moberg PJ, Kleiner-Fisman G, Duda JE, Stern MB, Mozley D, Katz IR. Weintraub D, et al. J Nucl Med. 2005 Feb;46(2):227-32. J Nucl Med. 2005. PMID: 15695780 Free article. Clinical Trial.

7

[99mTc]TRODAT-1 SPECT imaging correlates with odor identification in early Parkinson disease.

Siderowf A, Newberg A, Chou KL, Lloyd M, Colcher A, Hurtig HI, Stern MB, Doty RL, Mozley PD, Wintering N, Duda JE, Weintraub D, Moberg PJ. Siderowf A, et al. Neurology. 2005 May 24;64(10):1716-20. doi: 10.1212/01.WNL.0000161874.52302.5D. Neurology. 2005. PMID: 15911797

8

Rasagiline improves quality of life in patients with early Parkinson's disease.

Biglan KM, Schwid S, Eberly S, Blindauer K, Fahn S, Goren T, Kieburtz K, Oakes D, Plumb S, Siderowf A, Stern M, Shoulson I; Parkinson Study Group. Biglan KM, et al. Among authors: siderowf a. Mov Disord. 2006 May;21(5):616-23. doi: 10.1002/mds.20764. Mov Disord. 2006. PMID: 16450340 Clinical Trial.

9

Long-term effects of bilateral subthalamic nucleus stimulation on health-related quality of life in advanced Parkinson's disease.

Siderowf A, Jaggi JL, Xie SX, Loveland-Jones C, Leng L, Hurtig H, Colcher A, Stern M, Chou KL, Liang G, Maccarone H, Simuni T, Baltuch G. Siderowf A, et al. Mov Disord. 2006 Jun;21(6):746-53. doi: 10.1002/mds.20786. Mov Disord. 2006. PMID: 16463342 Clinical Trial.

10

Preclinical diagnosis of Parkinson's disease: are we there yet?

Siderowf A, Stern MB. Siderowf A, et al. Curr Neurol Neurosci Rep. 2006 Jul;6(4):295-301. doi: 10.1007/s11910-006-0021-z. Curr Neurol Neurosci Rep. 2006. PMID: 16822349 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

266 results

Search Page

Filters